Company profile ONCT

Oncternal Therapeutics Inc
oncternal therapeutics, inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. the company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ror1) that is in phase i/ii clinical trial in combination with ibrut...inib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in phase ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. it also develops tk-216, a small-molecule that is designed to inhibit e26 transformation specific family of oncoproteins, which is in phase i clinical trial to treat patients with ewing sarcoma and in combination with vincristine chemotherapy. in addition, the company develops a chimeric antigen receptor-t product candidate that targets ror1, whic Show More
Quarter analysis & expected interestLast update: February 09 2024 08:11:07.

After 39 days of this quarter the interest is at 205.0. Based on that we can calculate that during remaining 52 days it will total up to 478.0.
Oncternal Therapeutics expected interest is significantly higher compared to previous quarter (+658.7%) and same quarter last year (+158.4%).

YearQ1Q2Q3Q4
2019236
245
3.8% QoQ
224
-8.6% QoQ
88
-60.7% QoQ
2020 178
-24.6% YoY 102.3% QoQ
133
-45.7% YoY -25.3% QoQ
73
-67.4% YoY -45.1% QoQ
306
247.7% YoY 319.2% QoQ
2021 258
44.9% YoY -15.7% QoQ
302
127.1% YoY 17.1% QoQ
164
124.7% YoY -45.7% QoQ
110
-64.1% YoY -32.9% QoQ
2022 199
-22.9% YoY 80.9% QoQ
149
-50.7% YoY -25.1% QoQ
116
-29.3% YoY -22.1% QoQ
87
-20.9% YoY -25.0% QoQ
2023 185
-7.0% YoY 112.6% QoQ
153
2.7% YoY -17.3% QoQ
97
-16.4% YoY -36.6% QoQ
63
-27.6% YoY -35.1% QoQ
2024 205
10.8% YoY 225.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Oncternal Therapeutics search interestLast update: February 09 2024 08:11:06.
Correlation coefficient between keyword and revenue is 0.4
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 08:11:11.

The average 5 years interest of Oncternal Therapeutics was 13.68 per week.
The last year interest of Oncternal Therapeutics compared to the last 5 years has changed by -7.53%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -28.41%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 08:11:18.

After 39 days of this quarter the interest is at 25.0. Based on that we can calculate that during remaining 52 days it will total up to 58.0.
Oncternal Therapeutics stock expected interest is significantly higher compared to same quarter last year (+52.6%) but lower than previous quarter (-76.8%).

YearQ1Q2Q3Q4
201931
169
445.2% QoQ
135
-20.1% QoQ
84
-37.8% QoQ
2020 72
132.3% YoY -14.3% QoQ
67
-60.4% YoY -6.9% QoQ
67
-50.4% YoY 0.0% QoQ
140
66.7% YoY 109.0% QoQ
2021 197
173.6% YoY 40.7% QoQ
90
34.3% YoY -54.3% QoQ
261
289.6% YoY 190.0% QoQ
111
-20.7% YoY -57.5% QoQ
2022 90
-54.3% YoY -18.9% QoQ
57
-36.7% YoY -36.7% QoQ
28
-89.3% YoY -50.9% QoQ
127
14.4% YoY 353.6% QoQ
2023 38
-57.8% YoY -70.1% QoQ
116
103.5% YoY 205.3% QoQ
94
235.7% YoY -19.0% QoQ
250
96.9% YoY 166.0% QoQ
2024 25
-34.2% YoY -90.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Oncternal Therapeutics stock search interestLast update: February 09 2024 08:11:17.
Correlation coefficient between keyword and revenue is 0.68
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 08:11:19.

The average 5 years interest of Oncternal Therapeutics stock was 8.62 per week.
The last year interest of Oncternal Therapeutics stock compared to the last 5 years has changed by 8.24%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 4.6%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Oncternal Therapeutics news to provide analysis

Correlation between past revenue and Oncternal Therapeutics news search interest

There is not enough data for Oncternal Therapeutics news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Oncternal Therapeutics news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 08:11:25.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
zilovertamab expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201923
19
-17.4% QoQ
37
94.7% QoQ
41
10.8% QoQ
2020 109
373.9% YoY 165.9% QoQ
31
63.2% YoY -71.6% QoQ
25
-32.4% YoY -19.4% QoQ
108
163.4% YoY 332.0% QoQ
2021 52
-52.3% YoY -51.9% QoQ
25
-19.4% YoY -51.9% QoQ
105
320.0% YoY 320.0% QoQ
206
90.7% YoY 96.2% QoQ
2022 70
34.6% YoY -66.0% QoQ
93
272.0% YoY 32.9% QoQ
68
-35.2% YoY -26.9% QoQ
72
-65.0% YoY 5.9% QoQ
2023 39
-44.3% YoY -45.8% QoQ
165
77.4% YoY 323.1% QoQ
105
54.4% YoY -36.4% QoQ
131
81.9% YoY 24.8% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and zilovertamab search interestLast update: February 09 2024 08:11:23.
Correlation coefficient between keyword and revenue is 0.03
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 08:11:27.

The average 5 years interest of zilovertamab was 5.84 per week.
The last year interest of zilovertamab compared to the last 5 years has changed by 32.02%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 117.8%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ONCT-216 to provide analysis

Correlation between past revenue and ONCT-216 search interest

There is not enough data for ONCT-216 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ONCT-216 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ONCT-808 to provide analysis

Correlation between past revenue and ONCT-808 search interest

There is not enough data for ONCT-808 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ONCT-808 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ONCT-534 to provide analysis

Correlation between past revenue and ONCT-534 search interest

There is not enough data for ONCT-534 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ONCT-534 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Oncternal Therapeutics clinical trials to provide analysis

Correlation between past revenue and Oncternal Therapeutics clinical trials search interest

There is not enough data for Oncternal Therapeutics clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Oncternal Therapeutics clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Oncternal Therapeutics pipeline. to provide analysis

Correlation between past revenue and Oncternal Therapeutics pipeline. search interest

There is not enough data for Oncternal Therapeutics pipeline. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Oncternal Therapeutics pipeline. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ONCT
Earnings date: 2024-03-07 After close
Company name: Oncternal Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2025-07-01T12:00:00Z

GlobeNewswire
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

2025-04-10T12:30:00Z

BusinessWire
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

2025-03-07T21:05:00Z

GlobeNewswire
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC

2024-11-14T17:08:04-05:00

SEC
8-K Form - Current report, items 2.05 and 5.02 - Oncternal Therapeutics, Inc. (0001260990) (Filer)

2024-11-06T16:30:21-05:00

SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - Oncternal Therapeutics, Inc. (0001260990) (Filer)

2024-10-22T13:00:00Z

GlobeNewswire
Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

2024-10-15T12:12:22-04:00

SEC
144 Form - Report of proposed sale of securities - Oncternal Therapeutics, Inc. (0001260990) (Subject)

2024-09-12T16:49:42-04:00

SEC
8-K Form - Current report, items 2.05, 5.02, and 8.01 - Oncternal Therapeutics, Inc. (0001260990) (Filer)

2024-09-12T19:49:17Z

Analyst Upgrades
Northland Capital Markets Downgrades Oncternal Therapeutics to Market Perform, Announces $2 Price Target

2024-09-12T15:16:58Z

Analyst Upgrades
Brookline Capital Downgrades Oncternal Therapeutics to Hold

2024-09-12T13:00:00Z

GlobeNewswire
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives

2024-08-12T09:52:15Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $18

2024-08-10T01:46:01-04:00

Earnings Call Transcripts
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript

2024-08-08T16:30:22-04:00

SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - Oncternal Therapeutics, Inc. (0001260990) (Filer)

2024-08-08T16:10:15-04:00

SEC
8-K Form - Current report, items 2.02 and 9.01 - Oncternal Therapeutics, Inc. (0001260990) (Filer)